Opportunity Assessment for Strategic Planning

A clinical stage oncology company was developing oral therapies for high unmet need patient segments. It needed to assess the commercial opportunity for its lead asset within multiple biomarker positive populations.

Our team began by aligning on key business questions to help prioritize our primary and secondary research efforts. We then developed a comprehensive market landscape including key areas of unmet need, patient journey, treater dynamics, current and future treatment paradigms, and market size by patient segment. We then utilized secondary research to help develop focused discussion materials driving landscape evolution, product profile and market share discussions with HCPs (KOLs and high-prescribers) and payers (commercial insurers and PBMs). Finally, the team supported updates to key U.S. revenue forecast assumptions across biomarker populations and lines of therapy through our market research findings. We also provided high level ex-U.S. revenue multipliers across regions for a more comprehensive view of world-wide commercial opportunity.

The client used our outputs during leadership meetings to inform key decisions regarding strategic planning and go-to-market efforts for their lead asset. Moreover, our team’s perspectives and recommendations helped articulate the asset’s value proposition.